RPL17 and neoplasm: The use of immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1 antibodies) to restore CD8 + T cell activity as well as targeting inhibitory factors secreted by CSC (e.g., TGF-β inhibitors) may be helpful in tumor therapy.